Immuneering
$7.37
5
-$0.8-9.79% Friday 21:00
Statistics
Day High
8.12
Day Low
7.25
52W High
14.29
52W Low
3.7
Volume
71,549
Avg. Volume
77,291
Mkt Cap
215.71M
P/E Ratio
-3.96
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.6
-0.4
-0.2
0
Expected EPS
-0.46
Actual EPS
0
People Also Follow
This list is based on the watchlists of people on Stock Events who follow IMRX. It's not an investment recommendation.
Analyst Ratings
20.25$Average Price Target
The highest estimate is $25.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%
About
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Show more...
CEO
Employees
74
Country
US
ISIN
US45254E1073